RyanMichael TComminsMD

PubMed

• 43 citations
  Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2-M cell cycle arrest and enhanced vincristine sensitivity in Ewing’s sarcoma
  Stefan K. Zöllner, Saravana P. Selvanathan, Garrett T. Graham, Ryan M. T. Commins, Sung Hyeok Hong
  Science Signaling. 2017-10-03
• 10 citations
  Synthesis and structure-activity relationship studies of small molecule disruptors of EWS-FLI1 interactions in Ewing's sarcoma.
  Perrer N. Tosso, Yali Kong, Lauren M. Scher, Ryan Cummins, Jeffrey Schneider
  Journal of Medicinal Chemistry. 2014-12-12

Journal Articles

• Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2-M cell cycle arrest and enhanced vincristine sensitivity in Ewing's sarcoma  
  Zollner SK, Selvanathan SP, Graham GT, Commins RMT, Hong SH, Moseley E, Parks S, Haladyna JN, Erkizan HV, Dirksen U, Hogarty MD, Uren A, Toretsky JA, Science Signalling, 10/3/2017

Books/Book Chapters

• Conn's Current Therapy 2018 
  Chapter: High-Altitude Sickness 
  Page 1240 - 1243Adrienna Kovalsky and Ryan ComminsEditors: Rick D Kellerman and Edward T Bope.Elzevier, Philadelphia2017

Abstracts/Posters

• EWS-FLI1 targeted small molecule YK-4-279 synergizes with vinca alkaloids through double hit to mitotic machinery
  Zoller SK, Commins RMT, Selvanathan SP, Graham GT, Hong SH, Erkizan HV, Uren A, Toretsky JA, AACR Annual Meeting 2015, Philadelphia, PA, 2015
• Combinations of Current Chemotherapies with YK-4-279 in Ewing Sarcoma.
  Commins RMT, Hong SH, Barber-Rotenberg J, Uren A, Toretsky J, 16th Annual Meeting of the Connective Tissue Oncology Society, Chicago, IL, 10/1/2011